Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hs_BCell_Phospho_ORBI

ABSTRACT: Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas,ORBI

REANALYSIS of: PXD000658

INSTRUMENT(S): LTQ Orbitrap XL

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Others

SUBMITTER: Damian Fermin

PROVIDER: PAe005280 | PeptideAtlas |

REPOSITORIES: PeptideAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	PAe005280_10310_tandem.params	Other
	PAe005280_README	Other
	PAe005280_Search_Results_10310_201512301349.properties	Other
	PAe005280_Search_Results_10310_201512301349.tar.gz	Other
	PAe005280_mzXML_201512301348.properties	Other

Items per page:

1 - 5 of 8

Similar Datasets

Linking oncogenic signaling to transcriptional changes by epigenomic data in a cell line model of human glioblastoma

2013-01-01 | GSE36900 | GEO

Linking oncogenic signaling to transcriptional changes by epigenomic data in a cell line model of human glioblastoma

Project description:We present a computational method for building a regulatory network from global phosphoproteomic and transcription profiling data. To recover the critical missing links between signaling events and transcriptional responses, we relate changes in chromatin accessibility to changes in expression and then uses these links to connect proteomic and transcriptome data. We applied our approach to integrate epigenomic, phosphoproteomic and transcriptome changes induced by the variant III mutation of the epidermal growth factor receptor (EGFRvIII) in a cell line model of glioblastoma multiforme (GBM). Genome-wide DNase I hypersensitivity followed by sequencing (DNase-Seq) to measure chromatin accessibility in a cell line derived from the U87MG glioblastoma cell line to express high level of EGFRvIII (U87H; 2 million copies of EGFRvIII per cell) and a control cell line expressing kinase dead EGFRvIII (U87DK; 2 million kinase dead EGFRvIII per cell). A prediction from the computational method, the transcriptional co-regulator p300, was experimentally validated by chromatin immunoprecipitation followed by sequencing (ChIP-Seq).

2013-01-01 | E-GEOD-36900 | biostudies-arrayexpress

Hs_BCell_Phospho_FT

Project description:Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas,LTQFT

2014-12-31 | PAe005236 | PeptideAtlas

Arabidopsis thaliana

Project description:Arabidopsis thaliana Phosphoproteomic

| PRJNA946358 | ENA

Molecular characterization of BRSK2 and BRSK1 kinases as negative regulators of the NRF2 transcription factor

Project description:We found that the understudied Brain Specific Kinase 2 and 1 (BRSK2/1) proteins suppress NRF2-dependent transcription and NRF2 protein levels in a kinase-dependent fashion. Integrative phosphoproteomic screens, RNAseq profiling and follow-up validation studies revealed BRSK2/1-driven activation of AMPK and suppression of MTOR signaling. BRSK2 over-expression suppressed global protein synthesis and decreased ribosome-RNA associations, which results in decreased NRF2 protein levels. Overall, our data establish the BRSK1 and BRSK2 kinases as negative regulators of NRF2 via the AMPK/MTOR signaling axis.

2019-11-16 | GSE139135 | GEO

Automated Enrichment of Phosphotyrosine Peptides for High-Throughput Proteomics

Project description:Phosphotyrosine (pY) enrichment is critical for expanding fundamental and clinical understanding of cellular signaling by mass spectrometry-based proteomics. However, current pY enrichment methods exhibit a high cost per sample and limited reproducibility due to expensive affinity reagents and manual processing. We present rapid-robotic phosphotyrosine proteomics (R2-pY), which uses a magnetic particle processor and pY superbinders or antibodies. R2-pY can handle up to 96 samples in parallel, requires 2 days to go from cell lysate to mass spectrometry injections, and results in global proteomic, phosphoproteomic and tyrosine-specific phosphoproteomic samples. We benchmark the method on HeLa cells stimulated with pervanadate and serum and report over 4000 unique pY sites from 1 mg of peptide input, strong reproducibility between replicates, and phosphopeptide enrichment efficiencies above 99%. R2-pY extends our previously reported R2-P2 proteomic and global phosphoproteomic sample preparation framework, opening the door to large-scale studies of pY signaling in concert with global proteome and phosphoproteome profiling.

2023-05-05 | PXD041271 | Pride

Adaptive and reversible resistance to Kras inhibition in pancreatic cancer cells

Project description:Activating Kras mutations are the hallmark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and key drivers of PDAC initiation and progression. Despite increased efforts to develop novel Kras inhibitors, the degree of Kras oncogene addiction in PDAC cells remains unclear. Here, we analyzed the requirement of endogenous Kras for the maintenance of murine PDAC cells using an inducible shRNA-based system that enables temporal control of endogenous Kras expression. Surprisingly, the majority of murine PDAC cells analyzed tolerated acute and sustained Kras knockdown by adapting to a reversible cell state, characterized by differences in cell morphology, proliferative kinetics, and tumor-initiating capacity. While significant mutational or transcriptional changes were not observed in the Kras-inhibited state, global phosphoproteomic profiling revealed alterations in cell signaling, including increased phosphorylation of focal adhesion pathway components. Accordingly, Kras-inhibited cells displayed prominent focal adhesion plaque structures, enhanced adherence properties, and increased dependency on adhesion for viability in vitro. Our analyses highlight the possibility of adaptive non-genetic and non-transcriptional mechanisms of resistance to Kras inhibition. Furthermore, we have identified candidate proteins whose signaling activities are altered in the Kras-inhibited state, providing a basis for the rational design of combination therapeutic strategies with novel Kras inhibitors.

2018-01-03 | GSE95478 | GEO

Proteomic and phosphoproteomic data

Project description:Proteomic and phosphoproteomic data

| OEX00002200 | NODE

Expression data from lung SCC treated with DMSO and PXD101

Project description:We used microarrays to detail the global programme of gene expression in lung SCC cells treated with belinostat, a pan-HDAC inhibitor. The primary focus of this work is to investigate the efficacy of belinostat on lung SCC cells. Our phosphoproteomic profiling analyses revealed the downregulation of MAPK signaling pathway upon drug treatment, together with the induction of apoptosis. While HDAC inhibition generally affects transcription, the mechanism of SOS/MAPK downregulation was therefore proposed to be affected at the transcriptomic level. However, genes related to MAPK pathway were not significantly regulated upon belinostat treatment, whereas ubiquitin-proteasome gene signature was affected. This supports an indirect mechanism of epigenetic regulation on MAPK signaling that should be explored further.

2017-08-31 | GSE85979 | GEO

Protein expression of bladder cancer

Project description:Expression profiling of a total of 656 proteins in 3 high grade non-muslce invasive bladder cancer cases/normal urothelial mucosa pairs

2014-07-16 | GSE59440 | GEO